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Impact of in-house specialty pharmacy on access to novel androgen axis inhibitors in men with 
advanced prostate cancer. 
Anna Driscoll, Nathan Handley MD MBA*, Adam Binder MD, Siobhan Henry, W. Kevin Kelly DO 
 
Introduction: ​Novel androgen axis inhibitors are standard of care treatments in advanced prostate 
cancer. The billed amounts for these medications are often very high, which may create significant 
financial toxicity for patients and lead to delays in treatment. Our institution implemented an in-house 
specialty pharmacy in 2014, that provides these medications and evaluates copay assistance options for 
all patients. We evaluated the program’s impact on out of pocket cost (OOP) and turnaround time (TAT).  
 
Methods: ​We reviewed available internal specialty pharmacy records to identify prescriptions for 
abiraterone or enzalutamide filled between 1/1/17 and 12/31/18.  Payments were stratified by primary 
payment (amount reimbursed by the patient’s prescription plan based on the benefit’s design) and 
copayment assistance.  Turnaround times (TAT) in business days were stratified by prescriptions 
requiring intervention (prior authorization, copayment assistance, or insufficient inventory) and  clean 
prescriptions (those requiring no intervention). 
 
Results: ​One thousand four hundred seventeen prescriptions for 175 unique patients requiring 
abiraterone (n=869, 61.3%) or enzalutamide (n=548, 38.7%) were filled through the institution’s 
specialty pharmacy. The average amount paid by primary payer was $9,492.96 for a 30 day supply 
(range: $3,382.48-$12,939.84). Average quoted copay was $577.53 (range $3.08-$10,560.39). 64% of 
patients received copayment assistance. Average OOP cost per prescription after co-pay assistance was 
$100.83 (range $0-$8556.64). Three patients declined treatment due to cost (1.7% of overall). Average 
TAT was 2.98 days for clean prescriptions and 3.36 days for prescriptions needing intervention 
(p=0.055).  
 
Discussion: ​OOP cost varied significantly based on plan design and copayment assistance eligibility. The 
majority of patients received copayment assistance, which markedly reduced OOP cost. Cost rarely 
precluded access to treatment. TAT was not significantly prolonged for prescriptions requiring 
intervention. Further studies to determine impact of pharmacy type on access to specialty medications 
are indicated.  
 
 
